| Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2020: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2019: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2018: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Outline of Final Research Achievements |
Although flomoxef and cefmetazole has attracted substantial attention as an antibiotic against extended-spectrum beta-lactamase-producing Escherichia coli (ESBL-producing E. coli), the pharmacokinetics/pharmacodynamics (PK/PD) characteristics of flomoxef and cefmetazole against ESBL-producing E. coli is unclear. The aim of this study was to determine the PK/PD index of flomoxef and cefmetazole against ESBL-producing E. coli. Time-kill curves exhibited time-dependent activities. In neutropenic murine thigh infection experiments, the antibacterial activities of flomoxef and cefmetazole correlated with the time that the free drug concentration remaining above the minimum inhibitory concentration (MIC) (fT>MIC) The target values of fT>MIC for 1 log10 kill reduction were 35.1% for flomoxef and 69.6% for cefmetazole. Thus, fT>MIC is the most significant PK/PD index of flomoxef and cefmetazole against ESBL-producing E. coli and its target values are ≧40% and 70%, respectively.
|
